MedWatch

ALK upgrades guidance following convincing sales and savings

Allergy company ALK is turning up its guidance for the company's revenue and earnings for the whole year after sales have surprised positively, and after the firm has saved money on expenses and on timing its clinical development activities differently.

Photo: ALK / PR

Allergy and immune therapy company ALK reports better sales than predicted for the second quarter of the year. The company has also saved some money on certain expenses and on postponing certain clinical activities, so now the Danish company is upgrading its revenue and earnings guidance for full-year 2021, according to a Monday press release.

Whereas the Danish company previously forecast growth in the range of 9-12 percent measured in local currency, now it predicts to grow between 10-12 percent. This optimism is particularly due to the company's tablet sales, which have gone better than expected. Now, the company estimates tablet sales will grow 25 percent or more, whereas it previously projected growth of around 25 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs